Last updated: September 26, 2026
Glyburide and metformin hydrochloride is a mature, low-cost fixed-dose combination for type 2 diabetes. The product has no meaningful current U.S. brand exclusivity, faces broad generic competition, and has limited standalone revenue visibility. Commercial demand is constrained by clinical movement toward newer glucose-lowering agents and by concerns over glyburide-associated hypoglycemia. Patent risk is low for generic manufacturers, while manufacturing scale, regulatory compliance, payer pricing, and distribution access determine profitability.
What is glyburide and metformin hydrochloride used for?
Glyburide and metformin hydrochloride combines a sulfonylurea with a biguanide.
- Glyburide stimulates pancreatic insulin secretion.
- Metformin reduces hepatic glucose production and improves insulin sensitivity.
- The combination is used with diet and exercise to improve glycemic control in adults with type 2 diabetes.
The fixed-dose product was marketed in the United States under the brand Glucovance. U.S. labeling includes 1.25 mg/250 mg, 2.5 mg/500 mg, and 5 mg/500 mg tablet strengths, with dosing adjusted according to glycemic response and tolerability (U.S. Food and Drug Administration [FDA], 2009).
Glyburide carries a greater hypoglycemia concern than several newer sulfonylureas, particularly in older adults and patients with impaired renal function. The American Diabetes Association identifies hypoglycemia risk, weight gain, renal considerations, and treatment alternatives as important factors in selecting glucose-lowering therapy (American Diabetes Association Professional Practice Committee, 2024).
What is the FDA regulatory status of glyburide and metformin hydrochloride?
The combination is an FDA-approved small-molecule oral drug, not a biologic. It is regulated through the new drug application and abbreviated new drug application pathways.
| Regulatory item |
Status |
| Active ingredients |
Glyburide and metformin hydrochloride |
| Dosage form |
Immediate-release oral tablets |
| Original brand |
Glucovance |
| Original sponsor |
Bristol-Myers Squibb |
| FDA pathway |
NDA for the originator; ANDA for generics |
| Drug class |
Sulfonylurea plus biguanide |
| Biosimilar pathway |
Not applicable |
| Primary regulatory risk |
Bioequivalence, labeling, manufacturing, and quality compliance |
The product’s regulatory value is concentrated in its established safety database and recognized therapeutic use rather than in new chemical-entity exclusivity. FDA labeling warns about lactic acidosis associated with metformin and hypoglycemia associated with glyburide (FDA, 2009).
When did glyburide and metformin lose exclusivity?
The product is no longer protected by commercially meaningful U.S. market exclusivity. Glucovance was approved around 2000, and generic competition subsequently entered through ANDAs. Any original regulatory exclusivity associated with the NDA has expired.
The active ingredients are substantially older than the fixed-dose product. Their core composition-of-matter patent positions are therefore not commercially relevant to current U.S. market entry. A generic manufacturer generally does not face a live, high-value compound patent blocking supply of glyburide or metformin hydrochloride.
Exclusivity timeline
| Event |
Approximate timing |
Commercial effect |
| Glyburide and metformin established as separate therapies |
Before fixed-dose approval |
Mature active ingredients |
| Glucovance U.S. approval |
2000 |
Originator fixed-dose product launched |
| Generic ANDA development |
2000s onward |
Price competition increased |
| Brand exclusivity expiration |
Completed |
No current brand monopoly |
| Current market |
Mature generic stage |
Low unit economics and fragmented supply |
The precise patent and exclusivity record should be confirmed against the current FDA Orange Book and individual ANDA records because patent listings and regulatory status can change over time (FDA, 2024a).
What patents protect glyburide and metformin hydrochloride?
No high-value, unexpired U.S. composition patent is expected to protect the active ingredients. The commercial patent question is instead whether any formulation, process, polymorph, or method-of-use patent remains enforceable against a specific product.
For the immediate-release fixed-dose combination, the principal barriers are weak:
- The active ingredients are old.
- The dosage form is conventional.
- The product has multiple generic competitors.
- The core therapeutic use is established and broadly described.
- Generic substitution is supported by standard bioequivalence principles.
A formulation patent could theoretically cover release characteristics, excipient selection, tablet architecture, or manufacturing controls. Those claims would have to be materially different from a conventional immediate-release tablet and remain enforceable after patent-term adjustment. They would not normally create broad protection over every glyburide/metformin product.
How strong is the patent estate?
| Patent category |
Current strategic strength |
| Composition of matter |
Very low |
| Fixed-dose combination |
Low |
| Immediate-release formulation |
Low |
| Method of treatment |
Low to moderate, depending on claim scope and expiration |
| Manufacturing process |
Product-specific and usually avoidable |
| Pediatric or regulatory exclusivity |
No material current value expected |
| Biosimilar exclusivity |
Not applicable |
Patent strength is therefore low at the market level. A manufacturer could still face a product-specific patent dispute if it relies on a particular formulation or process, but such a dispute would not normally restore broad brand control.
What is the Orange Book status of glyburide and metformin hydrochloride?
The Orange Book is relevant to the original NDA and listed patents, but the product’s practical market status is generic. FDA’s Orange Book identifies approved drug products, therapeutic equivalence evaluations, and certain patent and exclusivity information (FDA, 2024a).
For commercial diligence, the key points are:
- The fixed-dose combination is eligible for generic substitution when an ANDA has an “AB” therapeutic-equivalence rating.
- Orange Book-listed patents associated with the original product do not automatically block every generic product after expiration.
- A generic applicant can use a Paragraph IV certification against an unexpired listed patent or a Paragraph III certification when launch follows patent expiration.
- Current patent listing status must be assessed at the specific NDA and ANDA level.
There is no commercial indication that the combination retains a broad Orange Book-based barrier to generic entry.
Which companies are challenging the brand, and what Paragraph IV risks exist?
Generic entry has already occurred. That means the principal Paragraph IV event is historical rather than a current threat to an unchallenged brand monopoly.
For a new generic applicant, Paragraph IV risk would depend on the presence of unexpired, listed patents tied to the reference product. The practical risk is limited because:
- The originator product is mature.
- Multiple generic products are already available.
- The active ingredients are off-patent.
- A challenger can often design around narrow formulation or process claims.
- Litigation economics are unattractive for a low-value combination product.
A Paragraph IV filing could still produce litigation under the Hatch-Waxman Act, including a 30-month stay of approval in some circumstances. The likely commercial outcome, however, would be additional generic competition rather than a high-value market transfer.
No major current U.S. patent litigation materially constraining the glyburide/metformin hydrochloride market is identified in the public regulatory sources cited here. Litigation status should be evaluated by NDA, ANDA, patent number, and defendant rather than by active ingredient alone.
What formulation patents protect glyburide and metformin tablets?
Conventional immediate-release tablets have limited formulation defensibility. Potential claim categories include:
- Specific excipient ratios
- Granulation or compression processes
- Stability improvements
- Dissolution profiles
- Bilayer or multilayer tablet construction
- Modified-release delivery systems
- Reduced gastrointestinal intolerance
- Dose-specific release characteristics
The marketed glyburide/metformin combination is generally associated with immediate-release tablets, not an innovative long-acting delivery platform. That limits the commercial value of formulation patents. A modified-release product could create a separate intellectual-property position, but it would require a distinct FDA approval and clinical or bioequivalence strategy.
What method-of-use patents apply to glyburide and metformin?
Method-of-use patent value is low because the combination’s principal use, treatment of type 2 diabetes, is well established. Narrower claims could address:
- A specific patient population
- Renal-function thresholds
- Titration protocols
- Combination use with another therapy
- Reduction of a defined adverse event
- Treatment sequencing
These claims would face challenges involving validity, written description, obviousness, and infringement by a generic label. Under FDA regulations, a generic applicant may seek a labeling carve-out for a patented method of use where permitted. That reduces the ability of a narrow method patent to block the entire market.
How does glyburide/metformin compare with newer diabetes drugs?
The combination competes against low-cost generic therapies and higher-priced branded agents. Its clinical and commercial position has weakened as treatment guidelines have expanded beyond glucose lowering.
| Therapy |
Relative cost |
Hypoglycemia risk |
Weight effect |
Market position |
| Glyburide/metformin |
Low |
Higher |
Weight gain possible |
Mature generic |
| Metformin alone |
Very low |
Low when used alone |
Neutral or modest loss |
Standard first-line option |
| DPP-4 inhibitors |
High versus generics |
Low |
Generally neutral |
Branded or generic class |
| SGLT2 inhibitors |
High |
Low when used alone |
Weight loss |
Strong growth and guideline support |
| GLP-1 receptor agonists |
High |
Low when used alone |
Significant weight loss |
High-growth branded segment |
| Insulin |
Variable |
High |
Weight gain possible |
Required for some patients |
SGLT2 inhibitors and GLP-1 receptor agonists have gained commercial importance because they offer cardiovascular, renal, or weight-management benefits beyond glucose reduction. Glyburide/metformin remains relevant where cost is the dominant consideration, but it has a weaker position in patients at elevated hypoglycemia risk or with cardiovascular and renal comorbidities.
What is the financial trajectory of glyburide and metformin hydrochloride?
Standalone revenue for glyburide/metformin hydrochloride is generally not disclosed by manufacturers because the product is sold as one item within broad generic portfolios. The financial trajectory is therefore best assessed through market structure rather than reported product revenue.
Revenue profile
The product has the following economic characteristics:
- Low average selling prices
- Limited brand premium
- High therapeutic substitution
- Multiple approved suppliers
- Significant pharmacy-benefit-manager pricing pressure
- Low differentiation among manufacturers
- Modest switching costs
- Potential supply volatility when manufacturers exit low-margin products
For a generic manufacturer, gross profit depends on tablet volume, procurement costs, manufacturing utilization, contract terms, and shortage conditions. The product is unlikely to be a major growth driver unless a supplier gains temporary share through a competitor withdrawal or supply disruption.
Market growth outlook
Volume growth is likely to remain flat to declining in developed markets. The main demand supports are:
- Continued prevalence of type 2 diabetes
- Low retail cost
- Availability in multiple strengths
- Use in cost-sensitive health systems
- Familiarity among prescribers
The main negative forces are:
- Greater use of metformin monotherapy or alternative combinations
- Reduced use of glyburide in older and renally impaired patients
- Increased prescribing of SGLT2 inhibitors and GLP-1 receptor agonists
- Clinical concern about hypoglycemia
- Generic price erosion
- Product discontinuations by low-margin suppliers
What generic launch scenarios exist?
Scenario 1: Stable generic market
Multiple manufacturers continue supply, prices remain low, and no supplier earns durable pricing power. This is the most likely base case.
Scenario 2: Temporary shortage-driven pricing
A manufacturer exits or experiences a quality problem. Remaining suppliers gain short-term volume and may obtain better pricing. The effect is usually temporary because other ANDA holders can increase production.
Scenario 3: Further demand erosion
Prescribers shift more patients to newer agents or safer alternatives. Glyburide/metformin volume declines, leading additional manufacturers to discontinue the product.
Scenario 4: Product repositioning
A manufacturer develops a differentiated modified-release or adherence-oriented product. This would require new regulatory work and potentially new intellectual property. The probability is low because the market has limited pricing headroom.
What manufacturing and IP barriers affect the market?
Manufacturing barriers are more important than patent barriers. Key requirements include:
- Consistent glyburide assay and content uniformity
- Metformin-related tablet size and tolerability control
- Validated dissolution performance
- Stability through labeled shelf life
- Control of nitrosamine and other impurity risks where applicable
- FDA-compliant current good manufacturing practices
- Reliable active pharmaceutical ingredient sourcing
- Scale-efficient packaging and distribution
The combination’s low selling price makes manufacturing efficiency essential. A supplier with a compliant facility and dependable API sourcing can compete effectively, but a facility remediation, warning letter, or supply interruption can quickly reduce market share.
Are there licensing deals associated with glyburide and metformin?
No major current licensing transaction is central to the product’s market outlook. The product is a mature generic combination rather than a platform technology or protected specialty medicine. Commercial arrangements are more likely to involve contract manufacturing, private-label supply, wholesaler distribution, or portfolio acquisitions than strategic licensing of proprietary rights.
Is there biosimilar risk for glyburide and metformin?
No. Glyburide and metformin hydrochloride are synthetic small molecules. Biosimilar regulation does not apply. Competitive risk comes from generic ANDAs, therapeutic substitution, branded diabetes drugs, and payer formulary management.
Key Takeaways
- Glyburide/metformin hydrochloride is a mature generic diabetes product with no meaningful current U.S. brand exclusivity.
- The active ingredients and conventional immediate-release combination have low patent strength.
- Paragraph IV litigation risk exists in principle but is unlikely to support a durable market barrier.
- Formulation and method-of-use patents would need narrow, product-specific claims to have commercial value.
- No biosimilar pathway applies.
- Revenue is not generally disclosed on a standalone basis and is likely modest relative to newer diabetes therapies.
- The commercial outlook is flat to declining in developed markets.
- Manufacturing reliability, regulatory compliance, API sourcing, and low-cost distribution are more important than patent protection.
- The strongest demand support is affordability; the largest clinical pressure is glyburide-associated hypoglycemia and competition from newer therapies.
FAQs
Is glyburide/metformin hydrochloride still prescribed?
Yes. It remains available as a generic option, particularly where treatment cost is a priority. Use is more selective in older adults and patients with renal impairment because of hypoglycemia and metformin safety considerations.
Can a generic manufacturer launch without licensing the original brand?
Usually, yes. A manufacturer can seek FDA approval through the ANDA pathway if it demonstrates pharmaceutical equivalence and bioequivalence and addresses applicable patent certifications.
Does metformin extend patent protection for glyburide?
No. Combining two old active ingredients does not automatically create new composition-of-matter protection. Any patent value would depend on a novel and enforceable combination, formulation, process, or use claim.
Why can a low-cost diabetes drug remain commercially available?
Large patient demand, established prescribing, low development costs, and use in cost-sensitive formularies can support continued supply even when margins are narrow. Availability can still fluctuate if manufacturers exit the market.
Could a new extended-release version create a stronger market position?
Potentially. An extended-release or otherwise differentiated formulation could support new regulatory and patent claims. Its commercial success would depend on clinical advantages, bioequivalence or clinical evidence, reimbursement, and whether the incremental benefit justifies a higher price.
References
American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024. Diabetes Care, 47(Supplement 1), S158-S178. https://doi.org/10.2337/dc24-S009
U.S. Food and Drug Administration. (2009). Glucovance (glyburide and metformin hydrochloride) tablets: Prescribing information. Bristol-Myers Squibb.
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
U.S. Food and Drug Administration. (2024b). Generic drugs: Questions and answers. https://www.fda.gov/drugs/questions-answers-generic-drugs
U.S. Food and Drug Administration. (2024c). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/generic-drug-user-fee-amendments人體藝術
